Freeline Therapeutics (FRLN) Institutional Ownership

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Stock Analysis Analyst Forecasts Earnings Headlines Ownership Short Interest Social Media

Current Institutional Ownership Percentage: 46.26%
Number of Institutional Buyers (last 12 months): 8
Total Institutional Inflows (last 12 months): $2.06M

Number of Institutional Sellers (last 12 months): 5
Total Institutional Outflows (last 12 months): $66.60M

Get FRLN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Freeline Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

FRLN Institutional Buying and Selling by Quarter

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

Freeline Therapeutics Major Shareholders & Ownership History

Export to Excel

Reporting Date	Major Shareholder Name	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/15/2024	Blue Owl Capital Holdings LP	86,654	$552K	0.1%	N/A	1.996%
2/15/2024	Sphera Funds Management LTD.	16,445	$105K	0.0%	N/A	0.379%
2/14/2024	PenderFund Capital Management Ltd.	60,401	$385K	0.0%	N/A	1.391%
2/9/2024	UBS Group AG	99,358	$633K	0.0%	+190.5%	2.289%
1/8/2024	Harbor Capital Advisors Inc.	20,352	$129K	0.0%	+62.8%	0.469%
11/13/2023	CHI Advisors LLC	86,654	$373K	0.1%	+300.0%	1.997%
Get the Latest News and Ratings for FRLN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/22/2023	CHI Advisors LLC	21,666	$56K	0.0%	-99.5%	0.499%
8/11/2023	Renaissance Technologies LLC	21,860	$56K	0.0%	-90.5%	0.504%
8/11/2023	Northern Trust Corp	15,659	$40K	0.0%	N/A	0.361%
7/27/2023	Syncona Portfolio Ltd	1,466,508	$3.78M	5.7%	-93.3%	33.791%
7/11/2023	Harbor Capital Advisors Inc.	10,709	$28K	0.0%	-90.1%	0.247%
5/12/2023	Renaissance Technologies LLC	230,600	$105K	0.0%	+17.4%	0.355%
5/12/2023	UBS Group AG	500,000	$228K	0.0%	-3.3%	0.770%
5/11/2023	CHI Advisors LLC	4,729,419	$2.15M	0.6%	-1.8%	7.279%
2/13/2023	Renaissance Technologies LLC	196,390	$93K	0.0%	-8.2%	0.302%
2/8/2023	Thrivent Financial for Lutherans	78,900	$37K	0.0%	N/A	0.121%
11/15/2022	TFG Asset Management GP Ltd	4,000,000	$2.80M	0.3%	+6.4%	6.156%
11/15/2022	Two Sigma Investments LP	50,905	$36K	0.0%	-25.2%	0.078%
11/14/2022	Renaissance Technologies LLC	214,000	$150K	0.0%	-19.3%	0.329%
10/28/2022	Harbor Capital Advisors Inc.	131,957	$92K	0.1%	-10.0%	0.203%
8/13/2022	Renaissance Technologies LLC	265,223	$231K	0.0%	-40.6%	0.425%
5/31/2022	Syncona Portfolio Ltd	21,997,620	$5.84M	5.6%	+645.7%	61.237%
5/17/2022	Eventide Asset Management LLC	3,606,192	$3.97M	0.1%	+3.5%	10.040%
5/16/2022	UBS Group AG	504,714	$565K	0.0%	N/A	1.405%
5/13/2022	Renaissance Technologies LLC	446,412	$500K	0.0%	+112.5%	1.243%
5/13/2022	Federated Hermes Inc.	60,000	$67K	0.0%	+50.0%	0.167%
5/12/2022	Acadian Asset Management LLC	26,963	$30K	0.0%	N/A	0.075%
5/4/2022	Prospera Financial Services Inc	34,650	$39K	0.0%	+130.3%	0.096%
5/3/2022	Values First Advisors Inc.	50,149	$56K	0.0%	+117.6%	0.140%
4/28/2022	Harbor Capital Advisors Inc.	144,672	$162K	0.1%	-20.7%	0.403%
3/10/2022	Values First Advisors Inc.	23,048	$46K	0.0%	N/A	0.064%
2/14/2022	Novo Holdings A S	1,776,613	$3.52M	0.2%	-7.9%	4.961%
2/11/2022	Syncona Portfolio Ltd	2,950,000	$5.84M	5.6%	N/A	8.237%
2/4/2022	Harbor Capital Advisors Inc.	182,521	$360K	0.1%	N/A	0.510%
11/16/2021	Wellington Management Group LLP	664,836	$2.29M	0.0%	-66.8%	1.857%
11/16/2021	CHI Advisors LLC	1,427,481	$4.87M	1.4%	+3.5%	3.987%
11/15/2021	Marshall Wace LLP	356,126	$1.23M	0.0%	N/A	0.995%
11/15/2021	Veritable L.P.	55,870	$191K	0.0%	N/A	0.156%
11/15/2021	AXA S.A.	566,207	$1.93M	0.0%	+1.9%	1.581%
11/12/2021	Renaissance Technologies LLC	194,500	$663K	0.0%	N/A	0.543%
Tiny Biotech Stock Wins $75 Billion Patent (Ad) A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda. Find out more here >>>
11/12/2021	Prospera Financial Services Inc	15,047	$51K	0.0%	N/A	0.042%
11/1/2021	SG Americas Securities LLC	47,390	$163K	0.0%	N/A	0.132%
8/16/2021	Federated Hermes Inc.	12,000	$98K	0.0%	-40.0%	0.033%
8/11/2021	CHI Advisors LLC	1,379,843	$11.25M	2.6%	-0.4%	3.850%
5/18/2021	Millennium Management LLC	66,851	$822K	0.0%	-7.2%	0.186%
5/17/2021	Ally Bridge Group NY LLC	408,726	$5.03M	1.0%	-3.8%	1.140%
5/14/2021	Sectoral Asset Management Inc	654,498	$8.05M	0.6%	-0.5%	1.825%
2/16/2021	Ovata Capital Management Ltd	14,981	$274K	0.1%	-60.1%	0.058%
2/13/2021	Polygon Management Ltd.	750,000	$13.70M	0.9%	+2.7%	2.893%
2/12/2021	CHI Advisors LLC	1,361,064	$24.85M	7.0%	+2.8%	5.251%
2/8/2021	FIL Ltd	157,968	$2.88M	0.0%	-40.6%	0.440%
11/16/2020	Hound Partners LLC	70,000	$1.09M	0.1%	N/A	0.270%
11/13/2020	Morgan Stanley	13,206	$206K	0.0%	N/A	0.051%
11/13/2020	AXA S.A.	549,154	$8.57M	0.0%	N/A	2.119%
11/13/2020	Ovata Capital Management Ltd	37,500	$585K	0.2%	N/A	0.145%
11/12/2020	Federated Hermes Inc.	20,000	$312K	0.0%	N/A	0.077%
11/9/2020	Caas Capital Management LP	18,166	$284K	0.0%	N/A	0.070%
11/5/2020	California Public Employees Retirement System	20,152	$315K	0.0%	N/A	0.078%

(Data available from 1/1/2016 forward)

FRLN Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of FRLN shares?: During the previous two years, 17 institutional investors and hedge funds held shares of Freeline Therapeutics. The most heavily invested institutionals were Eventide Asset Management LLC ($3.97M), Syncona Portfolio Ltd ($3.78M), TFG Asset Management GP Ltd ($2.80M), UBS Group AG ($633K), Blue Owl Capital Holdings LP ($552K), PenderFund Capital Management Ltd. ($385K), and CHI Advisors LLC ($373K).Learn more on FRLN's institutional investors.
What percentage of Freeline Therapeutics stock is owned by institutional investors?: 46.26% of Freeline Therapeutics stock is owned by institutional investors. Learn more on FRLN's institutional investor holdings.
Which institutional investors have been buying Freeline Therapeutics stock?: Of the 16 institutional investors that purchased Freeline Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Syncona Portfolio Ltd ($19.05M), UBS Group AG ($569.87K), Renaissance Technologies LLC ($270.52K), TFG Asset Management GP Ltd ($239.49K), Eventide Asset Management LLC ($120.54K), Blue Owl Capital Holdings LP ($86.65K), and Thrivent Financial for Lutherans ($78.90K).

How much institutional buying is happening at Freeline Therapeutics?: Institutional investors have bought a total of 20,672,600 shares in the last 24 months. This purchase volume represents approximately $341.18M in transactions.
Which Freeline Therapeutics major shareholders have been selling company stock?: The following institutional investors have sold Freeline Therapeutics stock in the last 24 months: Syncona Portfolio Ltd ($20.53M), CHI Advisors LLC ($4.79M), Renaissance Technologies LLC ($458.76K), Harbor Capital Advisors Inc. ($149.48K), Two Sigma Investments LP ($17.14K), and UBS Group AG ($16.93K).
How much institutional selling is happening at Freeline Therapeutics?: Institutional investors have sold a total of 25,966,165 shares in the last 24 months. This volume of shares sold represents approximately $70.60M in transactions.

Related Companies:

This page (NASDAQ:FRLN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Freeline Therapeutics (FRLN) Institutional Ownership

FRLN Institutional Buying and Selling by Quarter

Freeline Therapeutics Major Shareholders & Ownership History

FRLN Institutional Ownership - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Freeline Therapeutics (FRLN) Institutional Ownership

Institutional Ownership Changes (13F Filings) for Freeline Therapeutics (NASDAQ:FRLN)

FRLN Institutional Buying and Selling by Quarter

Freeline Therapeutics Major Shareholders & Ownership History

FRLN Institutional Ownership - Frequently Asked Questions